Overview

Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission

Status:
Recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This phase 2, open label, non-randomized study will evaluate the safety of administering high dose cytarabine (HiDAC) consolidation therapy on days 1-3 of each cycle, as compared to standard administration on days 1, 3, and 5 of each cycle, in patients 61 years and older with de novo acute myeloid leukemia (AML).

Phase:

Phase 2

Details

Lead Sponsor:

University of Florida

Treatments:

Cytarabine